Theliatinib, a novel EGFR TKI with strong affinity to wild type EGFR protein demonstrated dose-dependent anti-tumor activity in a panel of PDECX models with a generally good correlation between EGFR H score and tumor growth inhibition. This evidence concerns the gene EGFR and neoplasm.